EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti‐integrin therapy

John D Rioux iD, Gabrielle Boucher, Anik Forest, Bertrand Bouchard, Lise Coderre, Caroline Daneault, Isabelle Robillard Frayne, Julie Thompson Legault, Alain Bitton, Ashwin Ananthakrishnan, Sylvie Lesage iD, Ramnik J Xavier and 2 more

Immunology & Cell Biology · 2025-08 · 103 (7) · 648-663

DOI: 10.1111/imcb.70039 ↗

At a glance

Journal article in Immunology & Cell Biology, published online on 2025-06-12. Written by John D Rioux and 13 co-authors. Institution: Montreal Heart Institute Research Center, Montreal, QC, Canada. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Proteomics, Metabolomics, Integrins. Cited 7 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Canada Foundation for Innovation, NIDDK NIH HHS, Genome Canada.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise from an imbalance between its epithelial, immune and microbial components. It has been shown that biological differences (e.g. genetic, epigenetic, microbial, environmental) exist between patients with IBD. It is also known that there is important heterogeneity in the response to therapies that target very specific biological pathways (e.g. TNF‐alpha signaling, IL‐23R signaling, immune cell trafficking). The aim of this study was to identify potential biological differences associated with differential treatment response to the anti α4β7 integrin therapy known as vedolizumab. We performed targeted analyses of > 150 proteins and metabolites, and nontargeted analyses of > 1100 lipid entities in serum samples from 92 IBD patients (42 CD, 50 UC) immediately prior to initiation of therapy with vedolizumab (baseline samples) and at their first clinical assessment (week 14 samples). We detected that the baseline levels of multiple serum cytokines, amino acids, acylcarnitines and triglycerides were different between responders and nonresponders to treatment with vedolizumab. We also noted changes in serum analytes between baseline and week 14 samples that were different between these two groups of patients. Many of these serum analytes are markers of biological pathways that are involved in the activation, proliferation and metabolism of pro‐inflammatory cells. This study provides support for the hypothesis that biological differences between individuals not only impact the risk to develop IBD and IBD‐related clinical phenotypes but also an IBD patient's likelihood of responding to a biological therapy.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedProteomicsMetabolomicsIntegrinsInflammatory Bowel DiseasesCrohn DiseaseColitis, UlcerativeHumansFemaleMaleAdultMiddle AgedTreatment OutcomeBiomarkersSignal TransductionCytokinesYoung Adult

Author keywords

Crohn's diseasebiomarkerstreatment responseulcerative colitisvedolizumab

Substances

vedolizumabAntibodies, Monoclonal, HumanizedIntegrinsBiomarkersCytokines

Authors and institutions

  • Montreal Heart Institute Research Center, Montreal, QC, Canada.
  • Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
  • Maisonneuve-Rosemont Hospital Research Center, Montréal, QC, Canada.
  • Division of Gastroenterology, McGill University Health Centre, Montreal, QC, Canada.
  • Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.

ORCID profiles: John D Rioux, Sylvie Lesage

Funding

  • Canada Foundation for Innovation
  • NIDDK NIH HHS
  • Genome Canada
  • Canada Research Chairs
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Rioux, J. D., Boucher, G., Forest, A., Bouchard, B., Coderre, L., Daneault, C., Frayne, I. R., Legault, J. T., Bitton, A., Ananthakrishnan, A., Lesage, S., Xavier, R. J., Des Rosiers, C., & iGenoMed Consortium (2025). Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti‐integrin therapy. Immunology & Cell Biology, 103(7), 648-663. https://doi.org/10.1111/imcb.70039

Vancouver

Rioux JD, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C, et al. Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti‐integrin therapy. Immunology & Cell Biology. 2025;103(7):648-663. doi:10.1111/imcb.70039

BibTeX
@article{Rioux2025,
  author = {Rioux, John D and Boucher, Gabrielle and Forest, Anik and Bouchard, Bertrand and Coderre, Lise and Daneault, Caroline and Frayne, Isabelle Robillard and Legault, Julie Thompson and Bitton, Alain and Ananthakrishnan, Ashwin and Lesage, Sylvie and Xavier, Ramnik J and Des Rosiers, Christine and iGenoMed Consortium, iGenoMed Consortium},
  title = {Serum proteomic and metabolomic analyses from patients with IBD identify biological pathways associated with treatment success with anti‐integrin therapy},
  journal = {Immunology & Cell Biology},
  year = {2025},
  volume = {103},
  number = {7},
  pages = {648--663},
  doi = {10.1111/imcb.70039}
}
Start for free →